Pfizer's Xeljanz gets green light for treating active ankylosing spondylitis


Pfizer's Xeljanz drug was approved by the FDA to treat active ankylosing spondylitis in adults.

Xeljanz was approved under the supplemental New Drug Application, according to a Dec. 14 news release. The approval was based on a phase 3 trial in 269 adults with active ankylosing spondylitis.

"This regulatory approval affirms the clinical value and versatility of Xeljanz, the first and only Janus kinase inhibitor approved for five indications in the United States for the treatment of patients with certain immuno-inflammatory conditions," Mike Gladstone, Pfizer's global president of inflammation and immunology, said in the release.

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Podcast

Featured Whitepapers